Are cancers dependent on oncogenes or on aneuploidy? [3]

Cancer Genetics and Cytogenetics

Volumn 143, Issue 1, 2003, Pages 89-91

  Duesberg, Peter H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER; CANCER CELL; CARCINOGENESIS; COLON CANCER; CORRELATION ANALYSIS; GENE CONTROL; GENE FUNCTION; GENE INDUCTION; GENE MUTATION; GLIOBLASTOMA; HUMAN; LETTER; MELANOMA; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE N RAS; PATHOGENESIS; PHENOTYPE; POLYPLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0037992405     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00938-X     Document Type: Letter

References (35)

1. Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., Darnell J. Molecular cell biology. 4th edition:2000;W.H. Freeman, New York.
2. Duesberg P., Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton. 47:2000;81-107.
3. Weinstein I.B. Addiction to oncogenes. the Achilles heal of cancer Science. 297:2002;63-64.
4. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 24:2000;57-60.
5. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104.
6. Ewald D., Li M., Efrat S., Auer G., Wall R.J., Furth P.A., Hennighausen L. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science. 273:1996;1384-1386.
7. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 4:1999;199-207.
8. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W. 2nd, Cordon-Cardo C., Yancopoulos G.D., DePinho R.A. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
9. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin. induction of a complex neoplastic phenotype by a single oncogenic lesion Mol Cell. 3:1999;565-577.
10. Giaretti W., Monaco R., Pujic N., Rapallo A., Nigro S., Geido E. Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas. association with degree of DNA aneuploidy Am J Pathol. 149:1996;237-245.
11. Baisse B., Bouzourene H., Saraga E.P., Bosman F.T., Benhattar J. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 93:2001;346-352.
12. Konishi N., Hiasa Y., Matsuda H., Tao M., Tsuzuki T., Hayashi I., Kitahori Y., Shiraishi T., Yatani R., Shimazaki J., Lin I.C. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol. 147:1995;1112-1122.
13. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57:1997;524-531.
14. Albino A.P., Le Strange R., Oliff A.I., Furth M.E., Old L.J. Transforming ras genes from human melanoma. a manifestation of tumor heterogeneity? Nature. 308:1984;69-72.
15. van Elsas A., Zerp S., van der Flier S., Kruse-Wolters M., Vacca A., Ruiter D.J., Schrier P. Analysis of N-ras mutations in human cutaneous melanoma. tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis Recent Results Cancer Res. 139:1995;57-67.
16. Walch A., Bink K., Gais P., Stangl S., Hutzler P., Aubele M., Mueller J., Hofler H., Werner M. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol. 20:2000;25-32.
17. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K., Mihatsch M.J., Gudat F., Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:1993;2199-2203.
18. Strommer K., Hamou M.F., Diggelmann H., de Tribolet N. Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir (Wien). 107:1990;82-87.
19. Park S.H., Maeda T., Mohapatra G., Waldman F.M., Davis R.L., Feuerstein B.G. Heterogeneity, polyploidy, aneusomy, and 9p deletion in human glioblastoma multiforme. Cancer Genet Cytogenet. 83:1995;127-135.
20. Szollosi J., Balazs M., Feuerstein B.G., Benz C.C., Waldman F.M. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 55:1995;5400-5407.
21. Shen C.Y., Yu J.C., Lo Y.L., Kuo C.H., Yue C.T., Jou Y.S., Huang C.S., Lung J.C., Wu C.W. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma. an implication for mutator phenotype and breast cancer pathogenesis Cancer Res. 60:2000;3884-3892.
22. Plattner R., Anderson M.J., Sato K.Y., Fasching C.L., Der C.J., Stanbridge E.J. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci U S A. 93:1996;6665-6670.
23. Pollack J.R., Sorlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E., Tibshirani R., Botstein D., Borresen-Dale A.L., Brown P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A. 99:2002;12963-12968.
24. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
25. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., Vogelstein B., Kinzler K.W. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
26. Rasnick D., Duesberg P. How aneuploidy affects metabolic control and causes cancer. Biochem J. 340:1999;621-630.
27. Li R., Sonik A., Stindl R., Rasnick D., Duesberg P. Aneuploidy versus gene mutation hypothesis of cancer. recent study claims mutation, but is found to support aneuploidy Proc Natl Acad Sci U S A. 97:2000;3236-3241.
28. Marx J. Debate surges over the origins of genomic defects in cancer. Science. 297:2002;544-546.
29. Li R, Rasnick D, Duesberg P. Correspondence re: D. Zimonjic et al., Derivation of human tumor cells in vitro without widespread genomic instability [Cancer Res 2001;61:8838-44]. Cancer Res 2002;62:6345-8; author reply 6348-9.
30. Fabarius A., Willer A., Yerganian G., Hehlmann R., Duesberg P. Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. Proc Natl Acad Sci U S A. 99:2002;6778-6783.
31. Friehl J.P. Dorland's illustrated medical dictionary. 26th edition:1985;W.B. Saunders, Philadelphia.
32. Duesberg P., Rausch C., Rasnick D., Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A. 95:1998;13692-13697.
33. Duesberg P., Stindl R., Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A. 97:2000;14295-14300.
34. Duesberg P., Stindl R., Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes. chromosome reassortments catalyzed by aneuploidy Proc Natl Acad Sci U S A. 98:2001;11283-11288.
35. Duesberg P., Li R., Rasnick D., Rausch C., Willer A., Kraemer A., Yerganian G., Hehlmann R. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 119:2000;83-93.